Loading...
•
Mar 31, 2023
ACADIA Q1 2023 Earnings Report
Announced Q1 2023 financial results, highlighting the FDA approval and launch of DAYBUE and a 3% increase in NUPLAZID net sales.
Key Takeaways
Acadia Pharmaceuticals reported its Q1 2023 financial results, featuring the FDA approval and launch of DAYBUE for Rett syndrome and NUPLAZID net sales of $118.5 million, a 3% increase compared to Q1 2022. The company is also advancing its pipeline, including the completion of Phase 1 development for ACP-204 and nearing enrollment completion for the Phase 3 program for pimavanserin.
NUPLAZID net sales reached $118.5 million, a 3% increase compared to the same period last year.
DAYBUE received FDA approval for the treatment of Rett syndrome and was launched on April 17, 2023.
Phase 1 development program for ACP-204 has been completed.
Enrollment completion is nearing for the Phase 3 program for pimavanserin as a potential treatment for the negative symptoms of schizophrenia with top-line results expected in early 2024.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia is reiterating all of its 2023 guidance provided on February 27, 2023.
Positive Outlook
- NUPLAZID net sales in the range of $520 to $550 million.
- R&D expense in the range of $235 to $255 million, which includes approximately $20 million of stock-based compensation expense.
- SG&A expense in the range of $360 to $380 million, which includes approximately $45 million of stock-based compensation expense.